Reminyl Safety Signal Reported In Two Cognitive Impairment Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and foreign health authorities are investigating mortality rates from two galantamine studies in the treatment of mild cognitive impairment, Johnson & Johnson says. The studies did not demonstrate Reminyl efficacy in the indication.